Design and Characterizations of Inhalable Poly(lactic-


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
13 Mar 2020
Historique:
received: 27 02 2020
revised: 10 03 2020
accepted: 11 03 2020
entrez: 19 3 2020
pubmed: 19 3 2020
medline: 17 12 2020
Statut: epublish

Résumé

The present study aimed to develop inhalable poly (lactic-

Identifiants

pubmed: 32183032
pii: molecules25061311
doi: 10.3390/molecules25061311
pmc: PMC7144118
pii:
doi:

Substances chimiques

Delayed-Action Preparations 0
Powders 0
Polylactic Acid-Polyglycolic Acid Copolymer 1SIA8062RS
salmon calcitonin 7SFC6U2VI5
Calcitonin 9007-12-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 17K08453
Organisme : Japan Society for the Promotion of Science
ID : 17K15516
Organisme : Japan Society for the Promotion of Science
ID : 18K14885

Commentaires et corrections

Type : ErratumIn

Références

Nat Biotechnol. 1998 Feb;16(2):153-7
pubmed: 9487521
Nat Rev Drug Discov. 2019 Jan;18(1):19-40
pubmed: 30498202
AAPS PharmSciTech. 2014 Aug;15(4):882-97
pubmed: 24728868
Expert Opin Biol Ther. 2004 Jan;4(1):23-33
pubmed: 14680466
Protein Pept Lett. 2018;25(6):514-521
pubmed: 29848260
Biomed Pharmacother. 2018 Dec;108:828-837
pubmed: 30372894
Molecules. 2019 Apr 28;24(9):
pubmed: 31035401
Metabolism. 1984 Apr;33(4):295-303
pubmed: 6423929
J Control Release. 2009 Aug 19;138(1):16-23
pubmed: 19376169
Molecules. 2016 Sep 20;21(9):
pubmed: 27657028
Int J Pharm. 2015 Oct 30;494(2):611-618
pubmed: 25526674
Nanomedicine. 2010 Oct;6(5):662-71
pubmed: 20230912
Hum Vaccin Immunother. 2016 Mar 3;12(3):806-28
pubmed: 26513024
Pharm Res. 2004 Jul;21(7):1274-83
pubmed: 15290870
Eur J Biochem. 1994 May 1;221(3):1117-25
pubmed: 8181470
Int J Pharm. 2015 Oct 30;494(2):554-567
pubmed: 25772419
AAPS PharmSciTech. 2009;10(4):1252-62
pubmed: 19866362
Lancet. 1968 Jul 27;2(7561):217-8
pubmed: 4173429
Prog Biophys Mol Biol. 1993;59(3):237-84
pubmed: 8441810
Chem Biol Drug Des. 2013 Jan;81(1):136-47
pubmed: 23253135
J Allergy Clin Immunol. 2017 Jun;139(6):2013-2014.e1
pubmed: 28087325
Protein Sci. 1993 Mar;2(3):404-10
pubmed: 8453378
Pharm Res. 2016 Aug;33(8):1799-816
pubmed: 27174300
Am J Physiol. 1995 Sep;269(3 Pt 1):L394-402
pubmed: 7573474
Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110191
pubmed: 31923988
Curr Drug Deliv. 2019;16(3):180-194
pubmed: 30360739
Int J Mol Sci. 2011;12(12):9277-95
pubmed: 22272133
Pneumonol Alergol Pol. 2015;83(5):365-77
pubmed: 26378998
Nat Rev Drug Discov. 2007 Jan;6(1):67-74
pubmed: 17195033
J Control Release. 2020 Apr 10;320:265-282
pubmed: 31962095
J Food Sci. 2010 Aug 1;75(6):E394-400
pubmed: 20722925
Environ Geochem Health. 2012 Apr;34(2):279-88
pubmed: 21983883
J Pharm Sci. 1995 Jun;84(6):717-9
pubmed: 7562410
J Pharm Sci. 2008 Jul;97(7):2780-8
pubmed: 17894369
Amino Acids. 2006 Jun;30(4):351-67
pubmed: 16622600
Biochim Biophys Acta. 2005 Jun 30;1750(2):134-45
pubmed: 15964788
Molecules. 2017 Oct 12;22(10):
pubmed: 29023400
Ugeskr Laeger. 2019 Aug 12;181(33):
pubmed: 31495355
Curr Pharm Des. 2015;21(27):3867-74
pubmed: 26290195
J Control Release. 2007 Aug 16;121(1-2):3-9
pubmed: 17544538
Ther Deliv. 2015 Jan;6(1):41-58
pubmed: 25565440
Int J Pharm. 2017 Mar 15;519(1-2):213-219
pubmed: 28093327
J Control Release. 2019 May 10;301:176-189
pubmed: 30849445
Int J Biol Macromol. 2019 Aug 1;134:1022-1037
pubmed: 31128177
Int J Pharm. 2018 Sep 5;548(1):659-671
pubmed: 30033395

Auteurs

Hideyuki Sato (H)

Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Aiko Tabata (A)

Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Tatsuru Moritani (T)

Functional Material Development Center, Imaging Engine Development Division, RICOH Company, Ltd., 16-1 Honda-machi, Numazu-shi, Shizuoka 410-1458, Japan.

Tadahiko Morinaga (T)

Functional Material Development Center, Imaging Engine Development Division, RICOH Company, Ltd., 16-1 Honda-machi, Numazu-shi, Shizuoka 410-1458, Japan.

Takahiro Mizumoto (T)

ILS Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki 302-0104, Japan.

Yoshiki Seto (Y)

Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Satomi Onoue (S)

Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH